Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68592 | 0.84 | ESR1 (0.47) | TRPA1TAAR1SIGMAR1AOC3SLC6A2 | |
| SCHEMBL27090218 | 0.81 | TRPA1 (0.44) | TRPA1TAAR1AOC3SLC6A3RIPK1 | |
| SCHEMBL5150293 | 0.81 | ESR1 (0.50) | TRPA1TAAR1MTNR1AMTNR1BSIGMAR1 | |
| SCHEMBL28163887 | 0.78 | ESR1 (0.53) | MTNR1AMTNR1BSIGMAR1AOC3SLC6A2 | |
| SCHEMBL3674520 | 0.78 | TRPA1 (0.59) | TRPA1TAAR1AOC3SLC6A3RIPK1 | |
| SCHEMBL28859481 | 0.77 | ESR1 (0.47) | TRPA1TAAR1SIGMAR1SLC6A2MAOA | |
| SCHEMBL7201337 | 0.77 | ESR1 (0.47) | TRPA1TAAR1SIGMAR1SLC6A2MAOA | |
| SCHEMBL12816986 | 0.76 | MTNR1A (0.43) | TAAR1MTNR1AMTNR1BSIGMAR1SLC6A2 | |
| SCHEMBL10437920 | 0.75 | CYP19A1 (0.43) | MTNR1AMTNR1B | |
| SCHEMBL4752124 | 0.74 | MTNR1A (0.50) | TRPA1TAAR1MTNR1AMTNR1BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429669-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | TRPA1 1818/4885TAAR1 1121/4885MTNR1A 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.